-
effectivehealthcare.ahrq.gov/products/long-term-care-adults/research-protocol
December 20, 2011 - Assessing the Cost of Care
Assessing costs in the context of LTC requires attention to expenses associated … Meaningful cost comparisons between HCBS and institutional care must determine and specify the exact … Meanwhile, some cost analyses of HCBS include all public subsidies received by HCBS clients (e.g., rent … We will consider costs separately from the question of effectiveness; this review will not look at cost-effectiveness … Costs may include direct costs of care as well as costs such as resource utilization and family burden
-
effectivehealthcare.ahrq.gov/get-involved/nominated-topics/for-the-disabled-and-elderly-with-multiple-comorbidities-what-is-the-comparative-effectiveness-of-physician-housecalls-on-outcomes-and-total-cost
November 21, 2012 - comorbidities, what is the comparative effectiveness of physician housecalls on outcomes and total cost … There is little known about comparative mortality rates in this high-cost, complex, multi-morbid patients … The Independence at Home demonstration now underway will most likely confirm dramatic cost savings with … Newer studies confirm major cost savings, but my concern is that this might be related to the strong … Very little is known about housecalls beyond the cost savings.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/long-term-care-adults_research-protocol.pdf
December 20, 2011 - Assessing the Cost of Care
Assessing costs in the context of LTC requires attention to expenses associated … Meaningful cost comparisons between HCBS and
institutional care must determine and specify the exact … Meanwhile, some cost analyses of
HCBS include all public subsidies received by HCBS clients (e.g., … cost-effectiveness. … Costs may include direct costs of care as
well as costs such as resource utilization and family burden
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/mgmt-hnhc-patients-protocol.pdf
November 07, 2019 - success in these models depends, in large part, on
their effectiveness in addressing the care and costs … One direct approach is to identify the patients with the highest costs during a historical
time period … care
use/costs
No increased risk
for high health
care use/costs
Population: Identification of HNHC … patients (KQ 1 a-e)
HNHC patients:
High use/costs
are preventable or
modifiable
High use/costs … ACOs at a crossroads: costs, risk and MACRA. A NAACOS policy
white paper.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-future-presentation-format_research.pdf
January 01, 2019 - parameterize models (nonsystematic review,
systematic review, primary data, not stated); whether costs … proceed to calculate EVSI, the expected value of information from a sample n (and compare it to the costs … effectiveness plane scatter plot is a bivariate scatter plot
of costs (measured in dollars in this … The interviewer proposed that operational definitions of feasibility and future research costs
could … effectiveness analysis
2006 BMJ
18793033 Costs and effects of secondary prevention with perindopril
-
effectivehealthcare.ahrq.gov/products/health-data-mapping/protocol
December 03, 2019 - Partial economic evaluations and other cost analyses or descriptions are out of scope as costs are unable … We will note whether cost analyses were reported. … analysis that did not relate cost to effectiveness.
3/17/20
Table 1, Outcomes
INCLUDE … Partial economic evaluations and other cost analyses or descriptions are out of scope as costs are unable … The sentence on partial economic evaluations and other cost analyses was deleted based on the earlier
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/patient-generated-health-data-protocol-chronic-conditions.pdf
March 17, 2020 - Partial
economic evaluations and other cost analyses or descriptions are out of scope as
costs are … We will note
whether cost analyses
were reported. … analysis that did not relate
cost to effectiveness.
3/17/20 Table 1,
Outcomes
INCLUDE:
Process … Partial
economic
evaluations and
other cost analyses
or descriptions are
out of scope as
costs … The
sentence on partial economic
evaluations and other cost
analyses was deleted based
on the earlier
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/economic-evaluation-tools_research.pdf
October 01, 2012 - "
TX "cost analysis"
TX "economic analysis"
TX "Decision making"
TX "health policy"
TX reimbursement … Opportunity costs
b. Charges
c. Deflated charges (using cost-to-charge ratios)
d. … Type and adequacy of comparisons*
Costs
11. Cost perspective
12. Cost coverage
13. … Resources should be relevant to the perspective
and described in natural units before a cost
analysis … costs and effectiveness, and
incremental cost effectiveness ratios
25.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/long-term-care-adults-future_research.pdf
July 01, 2013 - Evidence was also insufficient for cost comparisons. … Evidence was also insufficient for cost comparisons. … Need to make cost comparisons that account for LTC costs and all other relevant costs,
including the … cost of room and board, costs of public subsidies (rent, transportation, and
food stamps), cost of … and unobserved variables that may create a
risk of bias
Interest among researchers
Duration
Cost
-
effectivehealthcare.ahrq.gov/sites/default/files/13_pulmonary_potential_high_impact_2012-12-11.pdf
January 01, 2012 - The
$294,000 annual cost of ivacaftor therapy was identified as a potentially controversial issue. … was set at about $294,000.
11
The manufacturer has implemented
stratified pricing terms based on … patient insurance status and income.
12
While ivacaftor’s annual
price is high, pricing was purported … The
$294,000 annual cost of ivacaftor therapy was identified as a potentially controversial issue. … representing a health systems
perspective estimated that treating all eligible patients with ivacaftor would cost
-
effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1312.pdf
December 01, 2013 - In October 2013, JAMA published an editorial (by O’Sullivan
and colleagues) on orphan-drug pricing, … indicating that pricing models are unsustainable and
using Kalydeco as an example. … for a monthly supply.11 The manufacturer has implemented
3
stratified pricing that is based … Although the cost of azithromycin therapy would be added to
current treatment costs, its low cost and … Pricing for
orphan drugs: will the market bear what society
cannot?
-
effectivehealthcare.ahrq.gov/sites/default/files/pulmonary-horizon-scan-high-impact-1306.pdf
June 01, 2013 - pharmacies.10 The manufacturer has implemented stratified pricing that is based on patient
insurance … Although the cost of azithromycin therapy would be
additive to current treatment costs, its low cost … perhaps even cost-saving impact.
8
References
1. … Kalydeco pricing. [internet]. Santa Monica (CA):
GoodRx, Inc. [accessed 2013 Jun 12]. [5 p]. … Azithromycin pricing. [internet]. Santa Monica (CA):
GoodRx, Inc. [accessed 2013 Jun 12]. [6 p].
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/prostate-cancer-surveillance_disposition-comments.pdf
December 01, 2011 - On a Medicare
allowable cost comparison basis, a full
course of CyberKnife SBRT costs
considerably … Two additional cost analyses to
consider are:
Corcoran AT, Peele PB, Benoit RM. … Cost
comparison between watchful waiting with
active surveillance and active treatment of
clinically … analysis of
prostate cancer treatments, and the
misconceptions regarding the costs of proton
therapy … Any cost
comparisons and economic evaluations
should either (i) not be included in the Final
Report
-
effectivehealthcare.ahrq.gov/sites/default/files/13_pulmonary_potential_high_impact_june_2012.pdf
January 01, 2012 - Ivacaftor costs about $294,000 per year, and some financial
analysts expect that third-party payers … Additionally, the manufacturer is expected to implement stratified pricing
terms based on patient insurance … patients aged 6
years and older who have a G551D mutation in the CFTR gene.
8
Ivacaftor’s annual pricing … was set
at about $294,000.
9
The manufacturer has implemented stratified pricing terms based on patient … insurance status and income.
10
While ivacaftor’s annual price is high, pricing was purported to
-
effectivehealthcare.ahrq.gov/sites/default/files/obesity-horizon-scan-high-impact-1306.pdf
July 01, 2013 - The cost of liraglutide at the dosage used to treat
obesity is expected to be greater than the cost … drug pricing resource GoodRX lists pricing for 30-day supplies ranging from $149.99 to
$159.99 at various … As of June 2013, the online U.S. drug pricing resource GoodRX
listed pricing for 30-day supplies ranging … can afford the cost. … Qsymia pricing. [internet]. Santa Monica (CA):
GoodRx, Inc.; 2012 Nov [accessed 2012 Nov 6].
-
effectivehealthcare.ahrq.gov/get-involved/nominated-topics/cost-effective-long-term-care-of-the-frail-elderly
February 18, 2011 - Cost effective long term care of the frail elderly
Does your question include a comparison of different
-
effectivehealthcare.ahrq.gov/products/diabetes-foot-ulcer-amputation-economics/research
March 08, 2011 - The cost of care for these beneficiaries is substantial, at about $33,000 for total reimbursement of … The actual national cost burden of diabetes is thought to exceed $174 billion, including the social cost … of intangibles such as pain and suffering, care provided by nonpaid caregivers, medical costs associated … with undiagnosed diabetes, and diabetes-attributed costs. … With this background in mind, the goal of this Data Points brief is to evaluate the utilization and costs
-
effectivehealthcare.ahrq.gov/sites/default/files/cer-216-telehealth-disposition-comments.pdf
April 24, 2019 - Profound changes in the
healthcare system overall are also rapidly impacting the costs and delivery … Regarding the cost model, w e acknow ledge that this
is not a typical approach. … How ever, the
simplicity of a cost-minimization analysis did not
w arrant a probabilistic sensitivity … We now have an
opportunity to begin to measure outcomes and costs in a consistent w ay. … analyses and
additional models.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-216-telehealth-disposition-comments.pdf
April 24, 2019 - Profound changes in the
healthcare system overall are also rapidly impacting the costs and delivery … Regarding the cost model, w e acknow ledge that this
is not a typical approach. … How ever, the
simplicity of a cost-minimization analysis did not
w arrant a probabilistic sensitivity … We now have an
opportunity to begin to measure outcomes and costs in a consistent w ay. … analyses and
additional models.
-
effectivehealthcare.ahrq.gov/products/high-utilizers-health-care
December 04, 2019 - Management of High-Need, High-Cost Patients: A Realist and Systematic Review
Timeline … December 04, 2019
Research Protocol
Management of High-Need, High-Cost